The North America High Throughput Process Development Market is poised for significant growth, driven by robust investments in biopharmaceutical research and advancements in automation technologies. The market is expected to experience a steady rise in demand for rapid process optimization and scalable solutions, serving a wide range of pharmaceutical and biotechnology companies across the region.
The economic impact of tariffs on "North America High Throughput Process Development Market".
Market Growth Drivers
Expansion of Biopharmaceutical R&D: Increasing investments by leading biopharmaceutical companies such as Pfizer and Amgen in research and development are propelling the demand for high throughput process development. The ability to screen thousands of process conditions in parallel accelerates drug development and shortens timeline to market. For instance, Amgen has incorporated advanced high throughput screening platforms at its Thousand Oaks facility, resulting in significant reduction in process development time. This trend is further magnified by the rising need for personalized medicines and complex biologics, which require rapid and efficient process optimization.
Technological Advancements and Automation: The integration of automation, robotics, and data analytics in high throughput process development is significantly transforming the industry landscape. Companies like GE Healthcare (now Cytiva) have developed automated liquid handling and analytics systems, enabling faster, reproducible, and cost-effective process optimization workflows. These technologies reduce manual labor, minimize human error, and enable organizations to handle increasingly complex processes, thereby increasing adoption rates across North American pharmaceutical and biotechnology sectors.
Market Trends
Adoption of Single-Use Technologies: The increasing shift towards single-use technologies in high throughput process development is a key market trend in North America. Companies like Thermo Fisher Scientific are launching innovative single-use bioreactors and microplates that enable rapid process development while reducing cross-contamination risks and cleaning validation time. This trend is especially significant in multi-product facilities and contract development and manufacturing organizations (CDMOs), helping to accelerate project turnaround and reduce operational costs.
Integration of Artificial Intelligence & Machine Learning: The use of AI and machine learning tools for data-driven experimentation and optimization is gaining momentum. For example, Sartorius has introduced AI-enabled analytics into its Ambr® platform, providing real-time predictive insights and automated adjustments. This trend enhances decision-making, improves yield and product quality, and enables predictive maintenance, turning high throughput process development into a smarter, more efficient activity for biopharmaceutical companies.
Market Opportunity
Expansion into Cell and Gene Therapy: The rapidly expanding cell and gene therapy sector in North America provides lucrative opportunities for high throughput process development solutions. Companies like Bluebird Bio and Novartis are seeking scalable, reproducible, and efficient manufacturing processes, and high throughput development platforms are essential to meeting these requirements, thus opening new revenue streams for technology providers.
Collaborative Research with Academic Institutions: Increasing partnerships between technology providers and leading academic research centers such as MIT and Harvard present new opportunities for innovation and validation of high throughput platforms, facilitating technology adoption and supporting translational research projects.
North America High Throughput Process Development Market Revenue, 2020-2035 (USD Million)
The chart illustrates a strong upward trajectory in the North America High Throughput Process Development Market from 2020 to 2035. Starting at USD 320 million in 2020, the market demonstrates consistent growth, reaching approximately USD 415 million by 2025 and projected to hit USD 1,210 million by 2035. The compounded annual growth rate (CAGR) of around 10.2% reflects the sector’s dynamic response to innovation, increasing biopharma investments, and the region's focus on rapid, flexible process development for advanced therapeutics. The notable acceleration post-2028 corresponds with the maturation of key enabling technologies and broader industry adoption.
North America High Throughput Process Development Market Share by Region, 2025 (%)
The 2025 pie chart highlights the regional share within North America for high throughput process development. The US dominates the market with a 75% share, owing to its extensive pharmaceutical and biotechnology industry network, robust funding, and a high concentration of leading players. Canada accounts for 16%, reflecting a growing focus on biomanufacturing and supportive government initiatives. Mexico, with 4%, is witnessing gradual adoption mainly from multinational partnerships and local bioproduction. The 'Rest of North America' category (3%) includes regions with emerging interest, while 'Others' (2%) cover new entrants and specialized local players. This distribution underscores the central role of the US in driving sectoral innovation and technology uptake.
Recent Market Developments
In February 2024, Cytiva announced the launch of a next-generation automated high throughput screening platform in collaboration with Canadian biotech firm AbCellera. The new platform accelerates antibody process development and doubles the throughput of previous models, integrating robotics and real-time analytics to streamline process optimization for biopharmaceutical clients across North America.
In April 2024, Thermo Fisher Scientific expanded its high throughput process development portfolio by introducing new single-use micro-bioreactor systems specifically designed for gene therapy applications. These systems enable parallel processing of up to 48 conditions, supporting rapid scalability and process parameter optimization in cell and gene therapy manufacturing, and have been adopted by leading US-based gene therapy research centers.
In May 2024, Sartorius partnered with Massachusetts Institute of Technology (MIT) for a multi-year collaborative research project to integrate advanced machine learning algorithms into high throughput development workflows. The joint effort aims to develop AI-driven models for real-time process monitoring, data-driven experiment planning, and predictive optimization, further bridging the gap between academic discovery and industrial scale-up.
Press Releases